Overview

Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Groups 2, 3 & 4)

Status:
Recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the feasibility of using a sub-therapeutic dose of a fluorine-18 analogue of NP-59 ([18F]FNP-59) to image the adrenal gland. Some participants are healthy normal subjects but have undergone interventions to manipulate hormones while other participants have known adrenal pathology.

Phase:

Early Phase 1

Details

Lead Sponsor:

Benjamin Viglianti

Treatments:

Cosyntropin
Dexamethasone